Posted by Michael Wonder on 10 Apr 2026
Celltrion’s ADC candidate CT-P71 wins FDA fast track in urothelial cancer
9 April 2026 - Celltrion announced Thursday that the US FDA has granted fast track designation to its antibody-drug conjugate candidate CT-P71 for patients with locally advanced or metastatic urothelial carcinoma who have received prior therapy.
This designation follows CT-P70’s fast track designation last December for metastatic non-squamous non-small cell lung cancer.
